Literature DB >> 19843675

Testosterone and biological characteristics of breast cancers in postmenopausal women.

Giorgio Secreto1, Elisabetta Venturelli, Elisabetta Meneghini, Marco Greco, Cristina Ferraris, Massimo Gion, Matelda Zancan, Aline S C Fabricio, Franco Berrino, Adalberto Cavalleri, Andrea Micheli.   

Abstract

Androgens are involved in the development of breast cancer, although the mechanisms remain unclear. To further investigate androgens in breast cancer, we examined the relations between serum testosterone and age, body mass index (BMI), tumor size, histologic type, grade, axillary node involvement, estrogen receptor status, progesterone receptor status, and HER2 overexpression in a cross-sectional study of 592 postmenopausal breast cancer patients. Mean testosterone differences according to categories of patient and tumor characteristics were assayed by Fisher's or Kruskall-Wallis test as appropriate; adjusted odds ratios (OR) of having a tumor characteristic by testosterone tertiles were estimated by logistic regression. Testosterone concentrations were significantly higher in women with BMI >or=30 versus BMI <25. ORs of having a tumor >or=2 cm increased significantly with increasing testosterone tertiles, and the association was stronger in women >/=65 years. The OR of having infiltrating ductal carcinoma was significantly higher in the highest compared with the lowest testosterone tertile. ORs of having estrogen receptor- and progesterone receptor-negative versus estrogen receptor- and progesterone receptor-positive tumors decreased significantly with increasing testosterone tertiles. In women >or=70 years, those with high testosterone had a significantly greater OR of HER2-negative cancer than those with low testosterone. These results support previous findings that high-circulating testosterone is a marker of hormone-dependent breast cancer. The age-related differences in the association of testosterone with other disease and patient characteristics suggest that breast cancers in older postmenopausal women differ markedly from those in younger postmenopausal women. The relationship between testosterone and HER2 status in the oldest patients merits further investigation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19843675     DOI: 10.1158/1055-9965.EPI-09-0540

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  7 in total

1.  Testosterone membrane-initiated action in breast cancer cells: Interaction with the androgen signaling pathway and EPOR.

Authors:  Vassiliki Pelekanou; George Notas; Elias Sanidas; Andreas Tsapis; Elias Castanas; Marilena Kampa
Journal:  Mol Oncol       Date:  2010-02-02       Impact factor: 6.603

2.  Sex steroid hormone levels in breast adipose tissue and serum in postmenopausal women.

Authors:  Roni T Falk; Elisabet Gentzschein; Frank Z Stanczyk; Montserrat Garcia-Closas; Jonine D Figueroa; Olga B Ioffe; Jolanta Lissowska; Louise A Brinton; Mark E Sherman
Journal:  Breast Cancer Res Treat       Date:  2011-08-26       Impact factor: 4.872

3.  Prospective case-control study of premenopausal serum estradiol and testosterone levels and breast cancer risk.

Authors:  Joanne F Dorgan; Frank Z Stanczyk; Lisa L Kahle; Louise A Brinton
Journal:  Breast Cancer Res       Date:  2010-11-18       Impact factor: 6.466

Review 4.  Post-menopausal breast cancer: from estrogen to androgen receptor.

Authors:  Avisek Majumder; Mahavir Singh; Suresh C Tyagi
Journal:  Oncotarget       Date:  2017-10-27

5.  Effectiveness of a Global Multidisciplinary Supportive and Educational Intervention in Thermal Resort on Anthropometric and Biological Parameters, and the Disease-Free Survival after Breast Cancer Treatment Completion (PACThe).

Authors:  Marie-Paule Vasson; Fabrice Kwiatkowski; Adrien Rossary; Sylvie Jouvency; Marie-Ange Mouret-Reynier; Martine Duclos; Isabelle Van Praagh-Doreau; Armelle Travade; Yves-Jean Bignon
Journal:  J Oncol       Date:  2020-05-05       Impact factor: 4.375

6.  Androgen receptors and serum testosterone levels identify different subsets of postmenopausal breast cancers.

Authors:  Giorgio Secreto; Elisabetta Venturelli; Elisabetta Meneghini; Maria Luisa Carcangiu; Biagio Paolini; Roberto Agresti; Cristina Pellitteri; Franco Berrino; Massimo Gion; Patrizia Cogliati; Giuseppina Saragò; Andrea Micheli
Journal:  BMC Cancer       Date:  2012-12-14       Impact factor: 4.430

7.  Observational study on the prognostic value of testosterone and adiposity in postmenopausal estrogen receptor positive breast cancer patients.

Authors:  Elisabetta Venturelli; Annalisa Orenti; Aline S C Fabricio; Giulia Garrone; Roberto Agresti; Biagio Paolini; Chiara Bonini; Massimo Gion; Franco Berrino; Christine Desmedt; Danila Coradini; Elia Biganzoli
Journal:  BMC Cancer       Date:  2018-06-13       Impact factor: 4.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.